Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data;Diagnostic spécifique et prise en charge des infections par un VIH-1 groupe O: données de RES-O

Medecine et Maladies Infectieuses

Volumn 40, Issue 12, 2010, Pages 669-676

  Depatureaux, A ^a   Leoz, M ^a   De Oliveira, F ^a   Gueudin, M ^a   Damond, F ^b   Descamps, D ^b   Brun Vezinet F ^b   Lemee V ^a   Simon, F ^c   Barin, F ^d   Plantier, J C ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

^b BICHAT HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

Charge virale VIH O; HIV 1 group O; HIV O viral load; Natural polymorphism; Natural resistance; Polymorphisme naturel; R sistance; VIH 1 groupe O

Indexed keywords

GLYCOPROTEIN GP 41; INTEGRASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP O INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT IDENTIFICATION; PATIENT MONITORING; SEROTYPING; VIRUS LOAD; VIRUS MUTATION;

EID: 78149398415     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.04.011     Document Type: Article

References (32)

1. Plantier J.C., Leoz M., Dickerson J.E., et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009, 15(8):871-872.
2. De Leys R., Vanderborght B., Vanden Haesevelde M., et al. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-Central African origin. J Virol 1990, 64:1207-1216.
3. Ayouba A., Mauclere P., Martin P.M., et al. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg Infect Dis 2001, 7(3):466-467.
4. Vessiere A., Rousset D., Kfutwah A., et al. Diagnosis and Monitoring of HIV-1 Group O-Infected Patients in Cameroun. J Acquir Immune Defic Syndr 2010, 53(1):107-110.
5. Hampl H., Sawitzky D., Stoffler-Meilicke M., et al. First case of HIV-1 subtype 0 infection in Germany. Infection 1995, 23(6):369-370.
6. Gurtler L.G., Hauser P.H., Eberle J., et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994, 68(3):1581-1585.
7. Rayfield M.A., Sullivan P., Bandea C.I., et al. HIV-1 group O virus identified for the first time in the United States. Emerg Infect Dis 1996, 2(3):209-212.
8. Cazein F., Pillonel J., Le Strat Y., et al. Surveillance of HIV and AIDS infection in France, 2007. Bull Epidemiol Hebd 2008, 45-46:434-443.
9. Van Heuverswyn F., Li Y., Neel C., et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006, 444(7116):164.
10. Jonassen T.O., Stene-Johansen K., Berg E.S., et al. Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s. Virology 1997, 231(1):43-47.
11. Archer J., Robertson D.L. Understanding the diversification of HIV-1 groups M and O. Aids 2007, 21(13):1693-1700.
12. Lemey P., Pybus O.G., Rambaut A., et al. The molecular population genetics of HIV-1 group O. Genetics 2004, 167(3):1059-1068.
13. Chaix-Baudier M.L., Chappey C., Burgard M., et al. First case of mother-to-infant HIV type 1 group O transmission and evolution of C2V3 sequences in the infected child French HIV Pediatric Cohort Study Group. AIDS Res Hum Retroviruses 1998, 14(1):15-23.
14. Gueudin M., Lemee V., Ferre V., et al. Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O. J Acquir Immune Defic Syndr 2004, 36(1):639-641.
15. Roques P., Robertson D.L., Souquiere S., et al. Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure. Virology 2002, 302(2):259-273.
16. Leoz M., Depatureaux A., Vessiere A., et al. Integrase polymorphism and HIV-1 group O diversity. Aids 2008, 22(10):1239-1243.
17. Plantier J.C., Djemai M., Lemee V., et al. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol 2009, 47(9):2906-2911.
18. Gueudin M., Plantier J.C., Lemee V., et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 2007, 44(5):500-505.
19. Descamps D., Collin G., Letourneur F., et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997, 71(11):8893-8898.
20. Plantier J.C., Leoz M., Depatureaux A., et al. Current resistance algorithms are not useful for HIV-1 group O-infected patients monitoring. 4th IAS Conference on HIV pathogenesis, treatment and prevention 2007.
21. Barin F., Plantier J.C., Brand D., et al. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J Med Virol 2006, 78(Suppl. 1):S13-S18.
22. Simon F., Souquiere S., Damond F., et al. Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses 2001, 17(10):937-952.
23. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(8):1596-1599.
24. Agut H., Candotti D., Rabanel B., et al. Isolation of atypical HIV-1-related retrovirus from AIDS patient. Lancet 1992, 340(8820):681-682.
25. Plantier J.C., Lemee V., Dorval I., et al. HIV-1 group M superinfection in an HIV-1 group O-infected patient. Aids 2004, 18(18):2444-2446.
26. Brand D., Beby-Defaux A., Mace M., et al. First identification of HIV-1 groups M and O dual infections in Europe. Aids 2004, 18(18):2425-2428.
27. Rapport 2008 sous la direction du Professeur Yeni. Prise en charge médicale des personnes infectées par le VIH. Médecine-Sciences Flammarion: Paris, France; 2008.
28. Desbois D., Roquebert B., Peytavin G., et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008, 52(4):1545-1548.
29. Tuaillon E., Gueudin M., Lemee V., et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004, 37(5):1543-1549.
30. Lataillade M., Chiarella J., Kozal M.J. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007, 12(4):563-570.
31. Chinnadurai R., Munch J., Dittmar M.T., Kirchhoff F. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. Aids 2005, 19(16):1919-1922.
32. Poveda E., Barreiro P., Rodes B., Soriano V. Enfuvirtide is active against HIV type 1 group O. AIDS Res Hum Retroviruses 2005, 21(6):583-585.